Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Diwakar DavarRoberta ZappasodiHong WangGirish S NaikTakami SatoTodd BauerDavid L BajorOlivier RixeWalter NewmanJingjing QiAliya HollandPhillip WongLianna SifferlenDiane PiperCynthia A SirardTaha MerghoubJedd D WolchokJason John LukePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
TRX518 showed an acceptable safety profile with pharmacodynamic activity. Repeated dose TRX518 monotherapy and in combination resulted in limited clinical responses associated with immune activation. See related commentary by Hernandez-Guerrero and Moreno, p. 3905.